Cargando…
Male gynecomastia and risk for malignant tumours – a cohort study
BACKGROUND: Men with gynecomastia may suffer from absolute or relative estrogen excess and their risk of different malignancies may be increased. We tested whether men with gynecomastia were at greater risk of developing cancer. METHODS: A cohort was formed of all the men having a histopathological...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC137592/ https://www.ncbi.nlm.nih.gov/pubmed/12383352 http://dx.doi.org/10.1186/1471-2407-2-26 |
_version_ | 1782120454320816128 |
---|---|
author | Olsson, H Bladstrom, A Alm, P |
author_facet | Olsson, H Bladstrom, A Alm, P |
author_sort | Olsson, H |
collection | PubMed |
description | BACKGROUND: Men with gynecomastia may suffer from absolute or relative estrogen excess and their risk of different malignancies may be increased. We tested whether men with gynecomastia were at greater risk of developing cancer. METHODS: A cohort was formed of all the men having a histopathological diagnosis of gynecomastia at the Department of Pathology, University of Lund, following an operation for either uni- or bilateral breast enlargement between 1970–1979. All possible causes of gynecomastia were accepted, such as endogenous or exogenous hormonal exposure as well as cases of unknown etiology. Prior to diagnosis of gynecomastia eight men had a diagnosis of prostate carcinoma, two men a diagnosis of unilateral breast cancer and one had Hodgkin's disease. These patients were included in the analyses. The final cohort of 446 men was matched to the Swedish Cancer Registry, Death Registry and General Population Registry. RESULTS: At the end of the follow up in December 1999, the cohort constituted 8375.2 person years of follow-up time. A total of 68 malignancies versus 66.07 expected were observed; SIR = 1.03 (95% CI 0.80–1.30). A significantly increased risk for testicular cancer; SIR = 5.82 (95% CI 1.20–17.00) and squamous cell carcinoma of the skin; SIR = 3.21 (95% CI 1.71–5.48) were noted. The increased risk appeared after 2 years of follow-up. A non-significantly increased risk for esophageal cancer was also seen while no new cases of male breast cancer were observed. However, in the prospective cohort, diagnostic operations for gynecomastia may substantially have reduced this risk CONCLUSIONS: There is a significant increased risk of testicular cancer and squamous cell carcinoma of the skin in men who have been operated on for gynecomastia. |
format | Text |
id | pubmed-137592 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2002 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-1375922002-12-08 Male gynecomastia and risk for malignant tumours – a cohort study Olsson, H Bladstrom, A Alm, P BMC Cancer Research Article BACKGROUND: Men with gynecomastia may suffer from absolute or relative estrogen excess and their risk of different malignancies may be increased. We tested whether men with gynecomastia were at greater risk of developing cancer. METHODS: A cohort was formed of all the men having a histopathological diagnosis of gynecomastia at the Department of Pathology, University of Lund, following an operation for either uni- or bilateral breast enlargement between 1970–1979. All possible causes of gynecomastia were accepted, such as endogenous or exogenous hormonal exposure as well as cases of unknown etiology. Prior to diagnosis of gynecomastia eight men had a diagnosis of prostate carcinoma, two men a diagnosis of unilateral breast cancer and one had Hodgkin's disease. These patients were included in the analyses. The final cohort of 446 men was matched to the Swedish Cancer Registry, Death Registry and General Population Registry. RESULTS: At the end of the follow up in December 1999, the cohort constituted 8375.2 person years of follow-up time. A total of 68 malignancies versus 66.07 expected were observed; SIR = 1.03 (95% CI 0.80–1.30). A significantly increased risk for testicular cancer; SIR = 5.82 (95% CI 1.20–17.00) and squamous cell carcinoma of the skin; SIR = 3.21 (95% CI 1.71–5.48) were noted. The increased risk appeared after 2 years of follow-up. A non-significantly increased risk for esophageal cancer was also seen while no new cases of male breast cancer were observed. However, in the prospective cohort, diagnostic operations for gynecomastia may substantially have reduced this risk CONCLUSIONS: There is a significant increased risk of testicular cancer and squamous cell carcinoma of the skin in men who have been operated on for gynecomastia. BioMed Central 2002-10-16 /pmc/articles/PMC137592/ /pubmed/12383352 http://dx.doi.org/10.1186/1471-2407-2-26 Text en Copyright © 2002 Olsson et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL. |
spellingShingle | Research Article Olsson, H Bladstrom, A Alm, P Male gynecomastia and risk for malignant tumours – a cohort study |
title | Male gynecomastia and risk for malignant tumours – a cohort study |
title_full | Male gynecomastia and risk for malignant tumours – a cohort study |
title_fullStr | Male gynecomastia and risk for malignant tumours – a cohort study |
title_full_unstemmed | Male gynecomastia and risk for malignant tumours – a cohort study |
title_short | Male gynecomastia and risk for malignant tumours – a cohort study |
title_sort | male gynecomastia and risk for malignant tumours – a cohort study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC137592/ https://www.ncbi.nlm.nih.gov/pubmed/12383352 http://dx.doi.org/10.1186/1471-2407-2-26 |
work_keys_str_mv | AT olssonh malegynecomastiaandriskformalignanttumoursacohortstudy AT bladstroma malegynecomastiaandriskformalignanttumoursacohortstudy AT almp malegynecomastiaandriskformalignanttumoursacohortstudy |